Aug. 24 at 9:18 PM
$VTVT
Bullish Arguments for VTVT at
$120
1️⃣.Strong clinical potential: Cadisegliatin could become a first-in-class oral therapy that significantly reduces hypoglycemia in Type 1 diabetes.
2️⃣. Major 2026 catalyst: Positive Phase 3 CATT1 results could trigger a major valuation re-rating.
3️⃣. Large upside vs. current valuation: If the drug proves effective and reaches a meaningful share of the T1D market, a multi-billion-dollar valuation—and potentially
$120/share—could be justified.
Bottom line:
$120 is a bull-case scenario driven by successful Phase 3 results, first-in-class potential, and significant commercial upside.
